// App-Quantinova.ai

10550 : Final report of randomized phase II study of two different outpatient setting regimens, vinorelbine (VNR) with cyclophosphamide (CPA) and temozolomide (TMZ) with etoposide (VP).

Researchers

Presenter

  • Atsushi Ogawa

Principal Investigators

  • Hiroshi Kawamoto

  • Mari Saito Oba

  • Ako Hosono

  • Yoshiyuki Kosaka

  • Junichi Hara

  • Yuji Ishida

  • Kenji Yamada

  • Katsuyoshi Koh

  • Yasuhiro Okamoto

  • Hideo Mugishima

  • Atsushi Kikuta

  • Takashi Taga

Medical Centers

  • Niigata Cancer Center, Niigata, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Teikyo University, Tokyo, Japan

  • National Cancer Center, EPOC, Chiba, Japan

  • Hyogo Children's Hospital, Kobe, Japan

  • Higashiosaka City General Hospital, Osaka, Japan

  • Shizuoka Cancer Center, Nagaizumi, Japan

  • Aichi Cancer Center Aichi Hospital, Okazaki, Japan

  • Saitama Children's Medical Center, Saitama, Japan

  • Kagoshima University Hospital, Kagoshima, Japan

  • Teikyo University, Tokyo, Japan

  • Fukusima Medical University, Fukushima, Japan

  • Shiga University of Medical Science, Otsu, Shiga, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Temozolomide

  • Vinorelbine

  • Etoposide

  • Etoposide phosphate

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Multicenteric

Phase

  • II

Study Id's

  • UMIN000003002

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved